Metastatic diseases of the central nervous system - neuropathologic aspects.

Metastatic diseases of the central nervous system - neuropathologic aspects. Handb Clin Neurol. 2018;149:67-73 Authors: Lopes MBS Abstract A large percentage of patients with cancer will develop brain metastases, and many of them will die within a few months following diagnosis of intracranial metastasis. Although the majority of the central nervous system metastases are derived from a well-known primary neoplasm, about 5-10% of brain metastases are from an unknown source, making the tissue diagnosis a first step in the search for a primary malignancy. The pathologist utilizes several immunohistochemical and molecular diagnostic tools for such investigation, helping the clinical oncologist to narrow down the clinical and radiologic exploration. Recently, analysis of actionable biomarkers for target therapy in brain metastasis has become significant due to reports of discrepancy of potential biomarkers between primary tumors and metastatic brain deposits. PMID: 29307362 [PubMed - in process]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Handb Clin Neurol Source Type: research

Related Links:

MiR‑500a‑5p promotes glioblastoma cell proliferation, migration and invasion by targeting chromodomain helicase DNA binding protein 5. Mol Med Rep. 2018 Jul 09;: Authors: Liu Z, Su D, Qi X, Ma J Abstract Glioblastoma is one of the most common malignant primary tumors and develops in brain. The molecular mechanism that regulates glioblastoma occurrence still remains unknown. MicroRNA (miR)‑500a‑5p has been reported to be involved in hepatocellular carcinoma and breast cancer. Whether miR‑500a‑5p regulates glioblastoma progression requires further investigation. In the present study, miR‑50...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Conclusions: WBRT remains the cornerstone of the management of brain metastases. The present study concludes that the survival of patients with brain metastases is significantly improved with female gender, good PS, primary breast cancer, time lag of>6 months between diagnosis of the primary tumor and development of brain metastases, solitary lesion, and controlled primary tumor.
Source: Indian Journal of Palliative Care - Category: Palliative Care Authors: Source Type: research
We presently forget 98% of everything we experience. That will go away in favor of perfect, controllable, configurable memory. Skills and knowledge will become commodities that can be purchased and installed. We will be able to feel exactly as we wish to feel at any given time. How we perceive the world will be mutable and subject to choice. How we think, the very fundamental basis of the mind, will also be mutable and subject to choice. We will merge with our machines, as Kurzweil puts it. The boundary between mind and computing device, between the individual and his or her tools, will blur. Over the course of the ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
When breast cancer reaches stage 4, it will have spread from the breast to other parts of the body. Cancer cells in new parts of the body can cause a wide variety of symptoms. Here, we explain the symptoms that occur when breast cancer spreads to the bones, liver, or brain. We also cover other symptoms and treatment.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Breast Cancer Source Type: news
Publication date: Available online 12 July 2018Source: NeuroImage: ClinicalAuthor(s): Alexandra C. Apple, Matthew P. Schroeder, Anthony J. Ryals, Lynne I. Wagner, David Cella, Pei-An Shih, James Reilly, FFrank J. Penedo, Joel L. Voss, Lei WangAbstractNearly three out of four survivors experience Cancer-Related Cognitive Impairment (CRCI) for months or years following treatment. Both clinical and animal studies point to the hippocampus as a likely brain region affected in CRCI, however no previous study has investigated the functional connectivity of the hippocampus in CRCI. We compared hippocampal connectivity in cancer su...
Source: NeuroImage: Clinical - Category: Radiology Source Type: research
ConclusionsGA highly merits to be studied in further animal models as an anticancer and chemoprotective drug.
Source: Chemico Biological Interactions - Category: Biochemistry Source Type: research
Publication date: June 2018Source: Clinical Epidemiology and Global Health, Volume 6, Issue 2Author(s): Atanu Bhattacharjee, Tapesh Bhattacharyya, Abin ThomasAbstractBackgroundBreast cancers with Human Epidermal Growth Factor Receptor 2 (HER2) borderline outcomes are very puzzling for patient management. To whether HER2 borderlines are having different prognostic status in comparison to HER2 positive/negative.MethodsThis is a study among women diagnosed with invasive breast cancer from 1973 to 2014 who were identified in the Surveillance, Epidemiology, and End Results (SEER) of 9 registries database and having diagnosed wi...
Source: Clinical Epidemiology and Global Health - Category: Epidemiology Source Type: research
Publication date: Available online 22 May 2018Source: Brain, Behavior, and ImmunityAuthor(s): Rita Haldar, Lee Shaashua, Hagar Lavon, Yasmin A. Lyons, Oded Zmora, Eran Sharon, Yehudit Birnbaum, Tanir Allweis, Anil K. Sood, Iris Barshack, Steve Cole, Shamgar Ben-EliyahuAbstractCatecholamines and prostaglandins are secreted abundantly during the perioperative period in response to stress and surgery, and were shown by translational studies to promote tumor metastasis. Here, in a phase-II biomarker clinical trial in breast cancer patients (n = 38), we tested the combined perioperative use of the β-blocker, propranolo...
Source: Brain, Behavior, and Immunity - Category: Neurology Source Type: research
ConclusionWe were unable to confirm previously reported findings, suggesting that individual SNPs are unlikely to be of clinical utility. Further investigations in well powered studies are warranted, which consider genetic heterogeneity according to subdomains of CRF.
Source: Brain, Behavior, and Immunity - Category: Neurology Source Type: research
Publication date: August 2018Source: Nanomedicine: Nanotechnology, Biology and Medicine, Volume 14, Issue 6Author(s): Man Li, Kairong Shi, Xian Tang, Jiaojie Wei, Xingli Cun, Yang Long, Zhirong Zhang, Qin HeAbstractCancer associated fibroblasts (CAFs) which shape the tumor microenvironment (TME) and the presence of blood brain barrier (BBB) remain great challenges in targeting breast cancer and its brain metastasis. Herein, we reported a strategy using PTX-loaded liposome co-modified with acid-cleavable folic acid (FA) and BBB transmigrating cell penetrating peptide dNP2 peptide (cFd-Lip/PTX) for enhanced delivery to ortho...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - Category: Nanotechnology Source Type: research
More News: Brain | Brain Cancers | Breast Cancer | Cancer | Cancer & Oncology | Neurology | Pathology